Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Is It Time To Get Into Merck Shares?

By (Jea Yu )Stock MarketsOct 19, 2021 06:28AM ET
Is It Time To Get Into Merck Shares?
By (Jea Yu )   |  Oct 19, 2021 06:28AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Pharmaceutical giant Merck & Company (NYSE:MRK) stock exploded to the upside on news of its game-changing COVID-19 pill Molnupiravir (molnu). The interim phase three clinical trial results showed a 50% reduction in hospitalization and a 100% reduction in deaths with no severe side effects. These results were so compelling that the Company is moving forward with emergency use approval (EUA) with the FDA and has bolstered the production capacity to 10 million treatments by the end of 2021 at an estimated price of $700 per pill and 10 pills per treatment/course.

While COVID-19 vaccination makers initially saw their share prices fall, it turns out that vaccinations are still needed and won’t be replaced by the pill. The Company also secured a deal with the U.S. government for 1.7 million courses upon FDA approval. Australia has agreed to a 300,000-course purchase. The mere announcement sent pandemic epicenter and reopening stocks back up spiking travel, lodging, hospitality, and retail stocks. The date for the FDA advisory committee review has been set for November 30, 2021. Prudent investors looking for exposure in this COVID-19 game-changer treatment can watch for an opportunistic pullback in shares of Merck.

Q2 FY 2021 Earnings Release

On July 29, 2021, Merck released its fiscal second-quarter 2021 results for the quarter ending June 2021. The Company reported an earnings-per-share (EPS) profit of $1.31 versus $1.35 consensus analyst estimates, a (-$0.04) miss. The Company saw revenues grow 21.9% year-over-year (YoY) to $11.4 billion beating analyst estimates for $11.2 billion. Keytruda sales rose 23% YoY to $4.2 billion. Gardasil sales grew 88% to $1.2 billion. Animal Health sales rose 34% to $1.5 billion.

Conference Call Takeaways

Merck CEO, Rob Davis, set the tone:

“Let me spend a moment speaking about KEYTRUDA, which again experienced very strong growth this quarter. I'm confident that KEYTRUDA will continue to be a foundational cancer therapy and achieve strong growth for years to come. We are a leader in immuno-oncology and are determined to leverage this into sustained success. We are rapidly advancing a diverse set of oncology assets, many of which we highlighted in our recent ASCO investor presentation. Across our oncology portfolio, we expect over 90 potential new indications by 2028, more than tripling our current base. We have a wide array of clinical partnerships, providing valuable insights into the biology of disease and into important potential external innovation. With our expanding oncology portfolio outside of KEYTRUDA, we will extend our leadership in cancer long into the future. I also strongly believe we will successfully navigate the eventual KEYTRUDA loss of exclusivity, given the breadth of opportunity in areas both within, as well as outside of oncology. Internally, our leaders are intensely focused on this period and efforts are underway.”

He concluded:

“We will be unbounded by therapeutic area, though we are mindful of the need to have a balanced portfolio over time. We'll seek new products, modalities, and platforms that allow us to establish beachheads in important areas. Our recent acquisition of Pandion and its potentially foundational immunology asset is a good example of this. We will look at both early and late-stage opportunities, and we have the financial flexibility to consider deals of all sizes, particularly given the $9 billion distribution from the Organon spinoff. And given our strong operational momentum, we are most interested in transactions that are easily integrated and less disruptive, where value is principally derived by the introduction of innovative new products that address patient needs instead of through cost energies.”

Merck Stock Chart
Merck Stock Chart

MRK Opportunistic Pullback Levels

Using the rifle charts on the weekly and daily time frames provides a precision view of the landscape for MRK stock. The weekly rifle chart peaked out near the $84.54 Fibonacci (fib) level. Shares have since been in pullback mode. The weekly breakout is attempting to form with a rising 5-period moving average (MA) crossover at $77.13 as the weekly stochastic crosses back up. The weekly upper Bollinger Bands (BBs) sit at $70.81. The weekly market structure high (MSH) sell triggered below $86.17 while the weekly market structure low (MSL) buy triggered on the breakout through $72.05. The daily rifle chart is forming a channel tightening and potential gap fill with the falling 5-period MA at $79.03 while testing the 15-period MA overshoots at $78.76. The daily gap fill area is the $76.65 when the news was announced. Prudent investors can look for opportunistic pullback levels at $76.65 fib, $75.46 fib, $73.38 fib, $72.26 fib, $70.52 fib, and the $69.32 fib level. Upside trajectories sit at the $84.54 fib upwards to the $96.89 fib level.

Original Post

Is It Time To Get Into Merck Shares?

Related Articles

Is It Time To Get Into Merck Shares?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email